aMoon is a global HealthTech and Life Sciences investment fund based in Israel. As Israel’s largest HealthTech fund, with $1.1 billion AUM, we partner with outstanding entrepreneurs who harness groundbreaking science and technology to transform healthcare.
Together with our portfolio companies, we work tirelessly to advance solutions that will help people live healthier, better lives.
We harness our unique team of over 50 scientists, physicians and entrepreneurs and our global network of investors and industry leaders to build bridges between our portfolio companies and global tech, finance and medical research hubs to help entrepreneurs turn their vision into reality.
Through our Velocity Fund we invest in companies pursuing disruptive, cutting-edge technologies as early as venture formation through Series A. Our Growth Fund invests in later-stage companies that are either generating revenue in growth rounds, pre-IPO rounds or in pivotal clinical trials.
Together with our portfolio companies, we work tirelessly to advance solutions that will help people live healthier, better lives.
We harness our unique team of over 50 scientists, physicians and entrepreneurs and our global network of investors and industry leaders to build bridges between our portfolio companies and global tech, finance and medical research hubs to help entrepreneurs turn their vision into reality.
Through our Velocity Fund we invest in companies pursuing disruptive, cutting-edge technologies as early as venture formation through Series A. Our Growth Fund invests in later-stage companies that are either generating revenue in growth rounds, pre-IPO rounds or in pivotal clinical trials.
Location: Israel, Center District, Raanana
Employees: 11-50
Founded date: 2016
Investors 1
| Date | Name | Website |
| - | Far East V... | fareast.ve... |
Mentions in press and media 35
| Date | Title | Description |
| 13.12.2024 | TX Ventures leads CHF 5 million round at Lyfegen | The healthcare industry faces increasing challenges with rising drug costs and the complexity of managing growing volumes of rebate agreements. For payers and pharmaceutical companies, manual processes often lead to inefficiencies, complia... |
| 06.11.2024 | PrognomiQ's $34 Million Boost: A New Dawn for Lung Cancer Detection | In the realm of healthcare, innovation is the lifeblood that fuels progress. PrognomiQ, a rising star in the diagnostics industry, has just secured a significant $34 million in Series D funding. This financial windfall, led by Seer, Inc., m... |
| 05.11.2024 | PrognomiQ Raises $34M to Advance Multi-Omics Early Detection Test for Lung Cancer | What You Should Know: – PrognomiQ, a healthcare company pioneering multi-omics approaches to disease detection, has secured $34M in Series D funding led by Seer, Inc., with participation from a new strategic investor and existing investors ... |
| 06.09.2023 | Ibex Medical Analytics Raises $55M to Drive AI for Cancer Diagnosis Adoption Globally | What You Should Know: – Ibex Medical Analytics (Ibex), a provider of AI-powered cancer diagnostics raises $55M in Series C financing round led by 83North. – The round also included participation from Sienna Venture Capital and existing inve... |
| 01.09.2023 | Better Life Partners Raises $26.5M to Expand Virtual SUD Platform | What You Should Know: – Better Life Partners, a virtual and in-person, community-embedded, whole-health solution for individuals and populations with substance use disorders (SUD) raises $26.5M in Series B funding round. – The round is co-l... |
| 30.11.2022 | Nectin Therapeutics Raises $25M for Immuno-Oncology Therapies | What You Should Know: The company also announced dosing of the first patient in its Phase 1 clinical trial of NTX1088, Nectin’s first-in-class PVR blocker, in cancer patients with locally advanced and metastatic solid tumors. NTX1088 is a f... |
| 23.09.2022 | Lyfegen raises $8M for its value-based drug contracting platform | Specialty medication prices in the U.S. are out of control. Despite making up about 2% of overall prescription volume, specialty drugs accounted for 53% of total annual pharmacy spending last year — up from 27% in 2010 — caused in part by g... |
| 21.09.2022 | Lyfegen secures $8 million to drive down drug costs | |
| 20.09.2022 | Lyfegen Raises $8M for Value-Based Contracting for High-Cost Drugs | What You Should Know: Currently, less than 2% of the health insurance population requiring specialty drugs is responsible for 51% of drug spending. The cost of specialty drugs in the US is spiraling out of control, increasing 12% from 2020 ... |
| 05.04.2022 | Eleos Closes $20M to Unlock CareOps Automation for Behavioral Health | What You Should Know: – Eleos Health has announced a $20 million Series A round, co-led by F-Prime Capital and Eight Roads Ventures, bringing their total raise to $28 million. – Eleos Health is a behavioral health application for voice AI, ... |
Show more